Dyne Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Dyne Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy Transcript
The story matters when it changes Dyne Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: official volume, pricing, inventory and segment margin.Dyne Therapeutics, Inc. Announces $200 Million Public Offering of Common Stock
Investors are testing whether Dyne Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now
Investors are testing whether Dyne Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest DYN filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Dyne Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →